Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;8(3):e59225.
doi: 10.1371/journal.pone.0059225. Epub 2013 Mar 15.

Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study

Affiliations

Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study

Daniel Tiller et al. PLoS One. 2013.

Abstract

Background/objectives: Chronic heart failure (CHF) is one of the most important public health concerns in the industrialized world having increasing incidence and prevalence. Although there are several studies describing the prevalence of heart failure with reduced ejection fraction (HFREF) and heart failure with normal ejection fraction (HFNEF) in selected populations, there are few data regarding the prevalence and the determinants of symptomatic heart failure in the general population.

Methods: Cross-sectional data of a population-based German sample (1,779 subjects aged 45-83 years) were analyzed to determine the prevalence and determinants of chronic SHF and HFNEF defined according to the European Society of Cardiology using symptoms, echocardiography and serum NT-proBNP. Prevalence was age-standardized to the German population as of December 31st, 2005.

Results: The overall age-standardized prevalence of symptomatic CHF was 7.7% (95%CI 6.0-9.8) for men and 9.0% (95%CI 7.0-11.5) for women. The prevalence of CHF strongly increased with age from 3.0% among 45-54- year-old subjects to 22.0% among 75-83- year-old subjects. Symptomatic HFREF could be shown in 48% (n = 78), symptomatic HFNEF in 52% (n = 85) of subjects with CHF. The age-standardized prevalence of HFREF was 3.8 % (95%CI 2.4-5.8) for women and 4.6 % (95%CI 3.6-6.3) for men. The age-standardized prevalence of HFNEF for women and men was 5.1 % (95%CI 3.8-7.0) and 3.0 % (95%CI 2.1-4.5), respectively. Persons with CHF were more likely to have hypertension (PR = 3.4; 95%CI 1.6-7.3) or to have had a previous myocardial infarction (PR = 2.5, 95%CI 1.8-3.5).

Conclusion: The prevalence of symptomatic CHF appears high in this population compared with other studies. While more women were affected by HFNEF than men, more male subjects suffered from HFREF. The high prevalence of symptomatic CHF seems likely to be mainly due to the high prevalence of cardiovascular risk factors in this population.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Algorithm to define symptomatic CHF.
Figure 2
Figure 2. Age-standardized prevalence of symptomatic CHF, HFREF and HFNEF (different denominators are due to by differences in the number of subjects with missing data for HFREF and HFNEF).
Figure 3
Figure 3. Age-specific prevalence of symptomatic CHF, HFREF and HFNEF by 5-year-age-groups.
Figure 4
Figure 4. Age-standardized prevalence of self-reported symptoms of CHF, NT-proBNP >220 pg/ml, systolic dysfunction and diastolic impairment as measured by echocardiography (regardless of any CHF diagnosis) (different denominators are due to by differences in the number of subjects with missing data for HFREF and HFNEF).
Figure 5
Figure 5. Prevalence ratio for the association of symptomatic HF (total, HFREF and HFNEF) with hypertension, CHD and myocardial infarction (adjusted for age and sex).

Similar articles

Cited by

References

    1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, et al. (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347: 1397–402. - PubMed
    1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933–989. - PubMed
    1. Luchner A, Burnett JC, Jougasaki M, Hense HW, Heid IM, et al. (2000) Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J of Hypertens 18: 1121–1128. - PubMed
    1. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, et al. (2006) Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 27: 3004–3010. - PubMed
    1. Vasan RS, Benjamin EJ, Levy D (1995) Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 26: 1565–1574. - PubMed

Publication types

Substances